Control of EHV-1 viremia and nasal shedding by commercial vaccines

L. S. Goehring, B. Wagner, R. Bigbie, S. B. Hussey, S. Rao, P. S. Morley, D. P. Lunn

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

Equine herpesvirus-1 is a cause of outbreaks of abortion and neurological disease. The pathogenesis of both these diseases depends on establishment of viremia. An experiment was performed to determine the protective efficacy of two commercially available vaccines used with an optimized 3-dose vaccination regime: a modified-live viral (MLV) and a high antigen load killed vaccine licensed for abortion control. The study design was a blinded, randomized challenge trial. Three groups of 8 yearling ponies received one of three treatments: MLV vaccine (Rhinomune®, Boehringer Ingelheim Vetmedica, Inc.); killed vaccine (Pneumabort-K®, Pfizer Animal Health); or a placebo (control group). Three vaccinations were administered at intervals of 27 and 70 days followed by challenge infection 24 days later. Clinical disease after challenge was significantly reduced in both vaccine groups; the reduction was greater in the MLV vaccine group. Nasal shedding was reduced by at least 1-2 logs in both vaccine groups. The number of days of viremia was significantly reduced in the killed vaccine group only. This study demonstrated that both commercial vaccines significantly suppressed EHV-1 disease and nasal viral shedding, and one vaccine suppressed days of viremia.

Original languageEnglish
Pages (from-to)5203-5211
Number of pages9
JournalVaccine
Volume28
Issue number32
DOIs
StatePublished - Jul 2010

Bibliographical note

Funding Information:
This project was funded by Fort Dodge Animal Health.

Keywords

  • EHV-1
  • Horses
  • Immunity
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Control of EHV-1 viremia and nasal shedding by commercial vaccines'. Together they form a unique fingerprint.

Cite this